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HIGHLIGHTS 
 The study did not show a statistically significant difference based on the Montgomery-
Asberg Depression Rating Scale (MADRS) score after 20 weeks of adjunctive N-
acetylcysteine (NAC) treatment compared to placebo 
 The MADRS score was reduced statistically significantly from baseline to week 20 in both 
study groups, and further reduced in the NAC study group at week 24 
 The mania score increased in the NAC treated group as compared to the placebo group 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 Page 2 
The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-
controlled study 
Running head: Add-on N-acetylcysteine for Bipolar Depression 
First author: PhD Pernille Kempel Ellegaard1,2,3* 
Second author: Professor, PhD, MD Rasmus Wentzer Licht4,5 
Third author: Associate professor, PhD, MD René Ernst Nielsen4,5 
Fourth author: PhD, Dr Olivia May Dean6,7,8 
Fifth author: Professor, MBBS Michael Berk6,7,8,9 
Sixth author: Professor, DMSci Henrik Enghusen Poulsen10,11 
Seventh author: PhD, Dr Mohammadreza Mohebbi12 
Eight author: PhD, MD Connie Thuroee Nielsen1,13 
 
Affiliations: 
1 Institute of Regional Health Services Research, Faculty of Health Sciences, University of Southern 
Denmark;  
2 Research Unit, Mental Health Service Esbjerg, The Region of Southern Denmark, Denmark;  
3 OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical 
Research, University of Southern Denmark, Odense C, Denmark;  
4 Unit for Psychiatric Research, Psychiatry, Aalborg University Hospital, Denmark;  
5 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 
6 Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, 
Geelong, Australia; 
7 Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, 
Australia; 
8 University of Melbourne, Department of Psychiatry, Royal Melbourne Hospital, Parkville, 
Australia; 
9 Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Victoria, Australia 
10 Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 
Denmark; 
11 Clinical Pharmacology, Bispebjerg Frederiksberg Hospital, Denmark; 
12 Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Australia; 
13 Mental Health Service Vejle, The Region of Southern Denmark, Denmark; 
 
Corresponding author: 
Pernille Kempel Ellegaard, 
Research Unit, Mental Health Service Esbjerg, Gl. Vardevej 101, 6715 Esbjerg N, Denmark; 
Telephone: +45 99 44 71 57. E-mail: Pernille.Ellegaard@rsyd.dk 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 Page 3 
 
Abstract 
Objective: To investigate the efficacy of adjunctive N-acetylcysteine (NAC) for the treatment of 
acute bipolar depression. 
Method: A randomized, double-blind, multicentre, placebo-controlled trial including adult subjects 
diagnosed with bipolar disorder, currently experiencing a depressive episode. Participants were 
treated with 3 g/day NAC or placebo as an adjunctive to standard treatment for 20 weeks, 
followed by a 4-week washout where the blinding was maintained. The primary outcome was the 
mean change in the Montgomery Asberg Depression Rating Scale (MADRS) score over the 20-week 
treatment phase. Linear Mixed Effects Repeated Measures (LMERM) was used for analysing the 
primary outcome. 
Results: A total of 80 subjects were included. The mean MADRS score at baseline was 30.1 and 
28.8 in participants randomized to NAC and placebo, respectively. Regarding the primary outcome 
measure, the between-group difference (NAC vs. placebo) was 0.5, which was statistically non-
significant (95% CI: -7.0 - 5.9; p= 0.88). All findings regarding secondary outcomes were statistically 
or clinically insignificant. 
Limitations: The study had a placebo response rate of 55.6% - high placebo response rates are 
associated with failure to separate from placebo. 
Conclusions: Based on our primary outcome measure, we could not confirm previous studies 
showing a therapeutic effect of adjunctive NAC treatment on acute bipolar depression. Further 
studies with larger samples are needed to elucidate if specific subgroups could benefit from 
adjunctive NAC treatment.  
KEYWORDS: Bipolar disorder, depression, N acetylcysteine, glutathione, treatment 
 
HIGHLIGHTS 
 The study did not show a statistically significant difference based on the Montgomery-
Asberg Depression Rating Scale (MADRS) score after 20 weeks of adjunctive N-
acetylcysteine (NAC) treatment compared to placebo 
 The MADRS score was reduced statistically significantly from baseline to week 20 in both 
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study groups, and further reduced in the NAC study group at week 24 
 The mania score decreased in the NAC treated group as compared to the placebo group 
INTRODUCTION 
Bipolar depression is challenging to treat, partly due to few available treatments (Grunze et al., 
2013). Therefore, search for new treatment options are warranted, and over the recent years, N-
acetylcysteine (NAC) has been examined in bipolar disorder (BD) and other mental and 
neuropsychiatric disorders (Berk et al., 2013; Dean et al., 2011; Deepmala et al., 2016; Minarini et 
al., 2017). Additionally, NAC has been used in other areas of medicine for almost four decades (D. 
and Conner, 1978) and is currently used for treating paracetamol overdose (Dringen and 
Hirrlinger, 2003), chronic obstructive pulmonary disease (Atkuri et al., 2007) and Human 
Immunodeficiency Virus-infection (Dodd et al., 2008).  
NAC has several mechanisms of action that make it potentially useful for the treatment of bipolar 
depression. Thus, NAC reduces oxidative stress (predominantly though the glutathione (GSH) 
system), and has also demonstrated anti-inflammatory properties (Zafarullah et al., 2003). BD is 
associated with an increased systemic inflammation, likely contributing to the pathophysiology 
(Berk et al., 2013), as it is believed that altered brain-derived neurotrophic factor and 
inflammatory cytokines are linked to cognitive impairment and neurodegeneration in the disorder 
(Duman and Monteggia, 2006; Hashimoto et al., 2004; Kim et al., 2007). Additionally, NAC 
modulates glutamate (Himi et al., 2003; Janaky et al., 2007), which has an impact on cognitive 
processing and mood states (Berk et al., 2007; Hashimoto et al., 2007). Previous Australian studies 
have demonstrated efficacy of adjunctive NAC for bipolar depression (Berk et al., 2008; Berk et al., 
2011). Thus, NAC 2 g/day used as an add-on to treatment as usual was shown to reduce the 
Montgomery-Asberg Depression Rating Scale (MADRS) score in a 24-weeks double blinded clinical 
trial as compared to placebo add-on(Berk et al., 2008). A similar result was found in an 8-week 
open clinical trial using adjunctive NAC 2 g/day treatment (Berk et al., 2011). However, a 20-weeks 
double blind maintenance study demonstrated no between-group differences between adjunctive 
NAC treatment and placebo, possibly due to all study participants receiving open label adjunctive 
NAC treatment the first eight weeks prior to randomization (Berk et al., 2012).                                                                                         
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Aims of the Study 
In the current study, we aimed at testing whether the previous positive findings could be 
replicated in a Danish study sample, by comparing the efficacy of NAC 3 g/day as add-on to 
treatment as usual compared with placebo add-on, in reducing symptoms of depression in 
subjects with bipolar depression, and whether the higher dose of NAC chosen here might even 
increase the magnitude of efficacy. The selected dose of NAC treatment has been reported to be 
well-tolerated (Prado et al., 2015; Sarris et al., 2015; Schmaal et al., 2011).   
MATERIAL AND METHODS 
Design 
The NACOS-study was a 20-week randomized, double-blind, placebo-controlled, parallel-group, 
multicentre trial with a 4-week wash-out period, with blinding upheld until last patient had had 
last visit. The subjects were informed that the last four weeks was a wash-out period where no 
study medication was provided. The study protocol is published elsewhere(Ellegaard et al., 2018). 
 
After informed consent was signed, the study participants were randomly allocated to NAC or 
placebo add-on according to a pre-constructed computer-generated randomization list divided 
into blocks of eight. There was no specific number of blocks allocated to study centre 1 and 2, 
however study centre 3 was allocated to one and a half block (Centre 1: Esbjerg, Varde and 
Broerup; centre 2: Fredericia, Vejle and Kolding; centre 3: Aalborg). Consecutively enrolled 
participants in each study centre received a randomization number at entry into the trial. Study 
visits were planned at week two, week 10, week 20 and week 24 (± seven days for each visit). 
Furthermore, participants were contacted via telephone six and 15 weeks after inclusion (± seven 
days) to support adherence. Un-blinding during the study was not necessary, but Glostrup 
Pharmacy could be contacted 24 hours a day, if un-blinding was necessary. The Mental Health 
Services facilities from three study centres covered three catchment areas; the centres were 
hospital based psychiatric settings, comprising both inpatient and outpatient units. The study 
procedures were conducted in the Mental Health Service clinics or alternatively as a home visits, 
whichever was most suitable for the participants. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 Page 6 
Ethics 
The trial was conducted in accordance with the Good Clinical Practice guidelines and the 
Declaration of Helsinki. The Good Clinical Practice Unit at Odense University Hospital and Aalborg 
Hospital monitored the study. The trial was approved by The Regional Scientific Ethical 
Committees for Southern Denmark: 35664-20120177. The study was registered at 
ClinicalTrials.Gov (NCT02294591), and the European Clinical Trials Database (EudraCT: 2012-
004483-22). 
Treatment 
Participants were randomized to 3 grams of NAC/day (1,500 grams (three capsules) twice daily) or 
placebo tablets identical in appearance, for 20 weeks in addition to Treatment-As-Usual (TAU) 
followed by four weeks washout, where only TAU was given. Standard mental care treatments 
including adjustment of psychopharmacological treatment or psychotherapy, initiation or 
discontinuation of ECT treatment were allowed throughout the study period. TAU was conducted 
by the clinical staff at the units where the patients were followed. 
 
Eligibility criteria and study withdrawal 
Inclusion criteria: 1) age from 18-64 years (both inclusive); 2) fulfilment of DSM-IV criteria for a BD 
(type I or II) (American Psychiatric Association, 2000), with a current depressive episode; 3) 
duration of episode at least four weeks; 4) a Montgomery-Asberg Depression Rating Scale score 
(MADRS) (Montgomery and Åsberg, 1979) score at entry of ≥ 18; 5) at least one documented 
affective episode within the last six months within the index period (depressive, manic or mixed), 
as judged by the principal investigator (according to the medical journal, and clinical interview 
based on the M.I.N.I), 6) written informed consent obtained; 7) female participants had to 
undergo a pregnancy test at baseline, and were required to be using a safe form of contraception 
(defined as birth control pills, mini-pills, intrauterine device or birth control implants), and accept 
that their male partners should use a condom. 
Diagnosis was confirmed by the use of the Mini International Neuropsychiatric Interview (M.I.N.I., 
version 5.0 in Danish) (Amorim et al., 1998; Lecrubier et al., 1998; Sheehan et al.).  
Exclusion criteria: 1) received electroconvulsive therapy (ECT) within the last four weeks prior to 
inclusion; 2) having a daily intake of more than 500 mg NAC, 200 μm selenium, or 500 IU of 
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vitamin E prior to inclusion; 3) recent bleeding in respiratory organs, asthma, epilepsy or any other 
medical condition that could interfere with study outcomes, as judged by an investigator; 4) 
allergy towards NAC, or being hypersensitive to histamine; 5) involuntary admission, detainment 
or treatment according to the statutes defined in the Mental Health Act; 6) not able to speak or 
understand the Danish language; 7) for females: breastfeeding or planned pregnancy during the 
timeframe of the study. 
Reason for study withdrawal: 1) serious adverse events suspected to be associated with the study 
treatment, based on an adverse rating scale; 2) severe suicidality during the trial, as judged by the 
investigator; 3) discontinuation of study treatment for seven or more consecutive days; 4) non-
compliance with the defined study visits (visit within seven days prior or after the computer-
generated date); 4) involuntary admission, detainment or treatment according to the statutes 
defined in the Mental Health Act; 5) withdrawal of consent; 6) for female participants: pregnancy 
or discontinuation of effective contraception. 
Assessments and outcome measures 
The primary outcome was the mean change from baseline up till week 20 in depressive symptoms 
as measured by the MADRS. The secondary outcomes were mean change in MADRS score from 
baseline up till week 24, as well as mean change on Bech-Rafaelsen Melancholia Scale (MES) 
(Bech, 2002a), Young Mania Rating Scale (YMRS) (Young et al., 1978), the WHO-Five Well-being 
Index (WHO-5) (Staehr Johansen, 1998), the Global Assessment of Functioning scale (GAF-F), the 
Global Assessment of Symptoms scale (GAF-S) (Jones et al., 1995) and the Clinical Global 
Impression-Severity Scale (CGI-S)) (Guy et al., 1976) at week 20 and up till week 24. The secondary 
outcomes included also proportions of responders (response defined as reduction of MADRS score 
≥ 50% compared with baseline) and remitters (remission defined as MADRS score < 10 (Hawley et 
al., 2002) at week 20 and week 24. 
The various rating scales were applied at weeks 0, 2, 10, 20 and 24. Additionally change in TAU 
during the trial, lifestyle behaviour (smoking, alcohol, substance use and BMI index) and treatment 
emergent adverse events or reactions were assessed and analysed. Adverse events and serious 
adverse events were reported by the study participants or healthcare professionals and 
documented at each study visit. Adherence was examined by counting all returned pills from each 
individual and thereby calculating days treated.  
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Statistical analysis  
Descriptive analyses including mean and SD or number and percentage reported and simple tests 
such as independent sample t-tests, chi-square or Fisher’s exact test were conducted on baseline 
variables to check for balance between the study groups in demographic data and other important 
participant characteristics. In all analyses participants were divided according to randomization. 
The analysis of the primary outcome measure was based on all randomized study participants 
Intention-To-Treat (ITT)-population and by using the Linear Mixed Effects Repeated Measures 
(LMERM) analyses (Laird and Ware, 1982; Mallinckrodt et al.). A Generalized Estimating Equation 
(GEE) (Feng et al., 2001) approach with unstructured covariance pattern was implemented to 
account for within patients autocorrelation across study visits. The LMERM-analysis included the 
fixed categorical study treatment, visits and visit by study treatment group two-way interaction 
(intervention impact). The two-way interaction of visits and study treatment group examines 
between groups baseline adjusted mean differences at each post baseline visit, and hence is used 
estimate intervention impact. We first examined the overall intervention impact (i.e. examining 
overall effect of visits and study treatment group two-way interactions at all post baseline visits) 
and then examined MADRS at week 20 as a linear contrast of the implemented LMERM, as this 
was the a priori defined primary outcome measure. Similar approach was used for all other 
continuous secondary outcomes. Logistic regression models (with allocation group as the only 
independent variable entered) were applied to estimate Odds Ratios (OR) for dichotomised 
variables such as response and remission based on participants completing 20 weeks intervention 
period. Side effects were analysed by using Fisher’s exact test. The Wilcoxon rank-sum test was 
used for comparing adherence and medical changes comparison between NAC and placebo. 
All tests of treatment effects were conducted using a two-sided alpha level of 0.05 and 95% 
confidence intervals (Cl) were reported. The sample size estimation was based on prior data from 
a similar clinical trial showing mean (SD) in MADRS score (from baseline to end of the study (week 
24)) was decreased by around 10.0 ± 4.3 and increased by around 0.9 ± 2.6 (in respectively the 
NAC and the placebo group (Berk et al., 2008), and with an aim of being able to detect a potential 
baseline-adjusted between-group mean difference of least 8 ± 10.0 at week 20, with 80% power 
and a two-sided alpha-level of 0.05, 80 people were needed, allowing for a 30% dropout rate. All 
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data analyses were performed by the statistical software program STATA IC, version 15 
(StataCorp., 2017), and in accordance with the International Conference on Harmonization E9 
statistical principles . 
RESULTS 
Sample characteristics and participant disposition 
A total of 192 patients were screened over a 2-year inclusion period (November 2014 until 
October 2016), with 80 patients out of these being randomized, equally distributed over time. A 
total of 53 people completed the intervention period (week 20); 26 in the NAC group and 27 in the 
placebo group (33.8% study withdrawals). Fifty-two participants completed the follow-up visit (24 
weeks) (35.0% study withdrawals) with 26 participants in both groups. The detailed participant 
disposition is displayed in the CONSORT flow diagram (figure 1). Participant characteristics except 
from outcome measures are shown in table 1. 
 
Figure 1 
 
INSERT APPROXIMATELY HERE  
Table 1:  
INSERT APPROXIMATELY HERE  
Except from two subjects in the NAC group, all participants received psychopharmacological 
treatment at baseline, most frequently antipsychotics, antidepressants and/or mood stabilizers, as 
shown in table 2. The mean number of psychotropic drugs prescribed at baseline was 3.8 (1.7), 
and there was a mean of 6.4 (2.9) psychopharmacological changes during the intervention period 
(increases, reductions, additions or/and discontinuations of treatment) with no differences 
between study groups (p=0.12) (data not shown).  
Table 2:  
INSERT APPROXIMATELY HERE 
 
Efficacy of study treatment on the primary outcome 
The LMERM-analysis showed no between-groups differences on mean change in MADRS scores 
(baseline adjusted) over the treatment phase (Intervention impact) ((NAC vs. placebo) 0.5; 95% CI: 
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-7.0, 5.9, p= 0.88) (table 3). The mean decline of the change in MADRS score from baseline to end 
of treatment (baseline unadjusted) was 13.8 points in participants allocated to NAC treatment as 
compared to 13.2 points in the placebo treated group. In addition, the overall intervention impact 
(i.e. testing all treatment by visits two-way interactions (simultaneously) showed no significant 
between group differences (p=0.53). The mean MADRS score at each visit between the two study 
groups are illustrated in figure 2. Results from the between-group comparisons from each study 
visit are shown in table 3. 
 
Figure 2:  
INSERT APPROXIMATELY HERE  
 
Table 3:  
INSERT APPROXIMATELY HERE 
 
Follow-up (week 24) visit 
As for the primary outcome analysis, the LMER -analysis showed no between-group difference in 
mean change (baseline adjusted) from baseline to week 24 was seen (p=0.15, 95% CI: -11.6, 1.8), 
but the intervention impact was decreased to -4.9 (table 3). The mean MADRS score from week 20 
to week 24 revealed a lower MADRS score in participants receiving NAC treatment compared to 
the placebo group corresponding to a decline in the mean MADRS score during these four weeks 
by 2.8 points in the NAC group and an increase by 1.3 points in the placebo group (table 3).  
 
Efficacy of study treatment on secondary outcomes 
The response rate from baseline to week 20 was 44.4% in the group receiving NAC treatment and 
55.6% in the placebo group ((NAC vs. placebo) OR 0.69, 95% CI: 0.2, 2.0, p=0.49). In the group 
allocated to NAC treatment 47.8% achieved remission as compared to 52.17% in the group 
allocated to placebo ((NAC vs. placebo) OR 1.09, 95% CI: 0.4, 3.2, p=0.88).  
After the extended four weeks blinded washout period, the response rate was 58.1% in the group 
allocated to NAC treatment group as compared to 42.0% in the group allocated to placebo 
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treatment ((NAC vs. placebo) OR 2.25, 95% CI: 0.7, 7.0, p=0.16), and for remission, a trend was 
found with 65.2% experiencing remission in the group allocated to NAC as compared to 34.8% in 
the group allocated to placebo ((NAC vs. placebo) OR 0.33, 95% CI: 0.1, 1.0, p=0.05). 
There were no significant differences in change in any of the other secondary outcomes between 
treatment groups, except a lower YMRS in the group allocated to NAC at week 20 (p < 0.03) (table 
3). 
 
Safety and tolerability 
In total, 66 adverse events were observed during the study (NAC group: n=39, placebo: n=27), with 
no between-group differences (OR 1.4, 95% CI: 0.8, 2.5, p=0.23) (Table 4). The most common 
adverse events were headache, diarrhoea, nausea and dizziness. Overall, 18 serious adverse 
events occurred during the study (NAC: n=10, placebo: n=8), with no difference between study 
groups (OR 2.0, 95% CI: 0.7, 6.1, p=0.20). These included five medical hospital admissions because 
of anaemia, influenza, pneumonia or alcohol intoxication, and the remainder were due to 
increased suicidal ideation (n=3) and psychiatric hospital admissions (n=10).  
 
Table 4: 
INSERT APPROXIMATELY HERE  
 
Posthoc analyses 
Based on the primary outcome, we explored whether the result would change, if only the more 
sensitive six-item subscale of MADRS (MADRS6) (Bech, 2002b) was used. The MADRS6 putatively 
covers the core symptoms of depression (Apparent and reported sadness, inner tension, lassitude, 
inability to feel, and pessimistic thoughts). However, a LMERM-analysis showed no between-group 
differences on the MADRS6 (p = 0.94).  
The psychopharmacological changes during the study were considered to possibly impact on 
outcome results, why changes in psychopharmacological treatment (from one drug to another or 
discontinuation) was included as a confounder in the LMERM-analysis, but did not change the 
primary result (95% CI: -7.0, 6.0, p = 0.89). Adherence to study medication during the trial was 
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evaluated based on calculation of all the returned pills from each participant and no between-
group difference was found.  
 
DISCUSSION 
In this 20-week trial, we were unable to show any difference on the primary measure, i.e. the 
mean change on the MADRS score, between participants treated with adjunctive NAC and 
participants treated with adjunctive placebo. Likewise, at week 24, i.e. four weeks after study 
medication discontinuation, no statistically significant between-group difference in the mean 
change on the MADRS score was seen. However, at week 24, there was a trend towards a higher 
remission rate in the NAC group (65.2%) as compared to the placebo group (34.8%) (p=0.05), 
reflecting a worsening in the MADRS score in the placebo group between week 20 and week 24. 
The four-week washout phase was incorporated into the study design to evaluate whether a 
potential superior effect of NAC as compared to placebo would be maintained after drug 
discontinuation. However, given that no superiority of NAC could be demonstrated during the 
treatment phase, any interpretation of this secondary finding besides considering it as a type one 
error is speculative, like e.g. that the relatively large placebo effect (see below) diluted a minor 
effect of NAC, an effect that became observable after the placebo effect disappeared in both 
groups. 
Two out of the three previously published efficacy studies of NAC treatment in BD were positive 
and one was negative (Berk et al., 2008; Berk et al., 2011; Berk et al., 2012). The eligibility criteria 
of these studies were similar to the current study. Compared to the previous studies, in the 
present study a higher dose of NAC treatment was administered, changes in 
psychopharmacological treatment prior to inclusion were allowed and participants were more 
severely depressed. These factors might have impacted the outcome of the study. Additionally, 
the use of a pre-defined baseline severity for inclusion may have increased the risk of inflated 
baseline scores, resulting in apparent increased treatment response in both groups, thereby 
minimizing potential between-group differences (Fournier et al., 2010; Landin et al., 2000).  
Our study investigated adjunctive treatment to TAU to reflect real world clinical practice. In 
studies investigating the efficacy of adjunctive treatment it is difficult to detect a difference 
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between study groups, since it has to generate efficacy in addition to an already established 
treatment. This is especially the case if the established treatment is initiated shortly prior to the 
study or if it can be changed during the trial by the clinician, as placebo treated patients not 
experiencing any improvement most likely will undergo changes in pharmacological or 
psychotherapeutic treatment to improve their condition. On the other hand, patients in the 
current study were experiencing an acute episode of depression and a pure placebo add-on 
treatment arm, without the possibility of adjusting background treatment for the study duration 
of 24 weeks was not judged ethically acceptable and would most likely also have resulted in more 
drop-outs. However, if NAC treatment was effective, we could have expected fewer alternations in 
the NAC group than in the placebo group during the study; such a difference was not observed, 
thus lending further support to the null hypothesis of no true antidepressant effect of NAC in 
bipolar depression. The anticipated NAC effect used in sample size calculation was optimistic and 
in addition dropout rate was higher than expected. As such the study might have been 
underpowered and this could be another reason why treatment effect was not statistical 
significant. 
Adherence to medication in patients diagnosed with bipolar disorder has been shown to be low 
with a median medication possession ratio of approximately fifty percent (REF)(Berk and Berk, 
2003; Greene et al., 2018). In the current study we utilized pill counts of returned packages of 
medication to calculate an adherence rate, showing no significant difference between study 
groups. Other methods to estimate adherence have been proposed such as electronic pill bottles, 
although are rarely used(Vrijens and Urquhart, 2014).  
In the placebo group, we found a mean reduction in MADRS scores of 55.6% over 20 weeks, which 
is higher than previously found by Berk et al, who observed a 21.0% reduction over 20 weeks in 
the placebo group (Berk et al., 2008). In general, studies with high placebo response rates are 
likely to result in absence of an efficacy signal from any treatment, which should be taken into 
consideration in the interpretation of our negative results. 
 
The main strengths of the current study were the use of a randomized double-blind placebo-
controlled design and the fact that the planned study sample was achieved. Also, the allowance of 
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medication changes throughout the study period increased the generalizability and clinical utility 
of the results. 
In conclusion, despite a sufficient sample size adjunctive NAC treatment showed no superiority to 
placebo in terms of efficacy in any of the psychometric outcome measures from baseline to week 
20 except from the YMRS, which was clinically insignificant. The findings emphasize the challenge 
of interpreting negative findings of clinical trials when placebo response rates are high. Also, the 
fluctuations of mood over time in BD calls for development of more sensitive outcome measures. 
Currently, studies have shown effect of NAC in the treatment of depression in patients diagnosed with 
bipolar disorder(Berk et al., 2008; Berk et al., 2011). The treatment is generally well-tolerated and the 
current treatment armamentarium for treating depression in patient diagnosed with bipolar disorder is 
small. As a result, we would suggest further studies are needed to clarify whether NAC has an effect against 
depression in this population and if the medication should be recommended as a possible treatment 
option.  
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TABLES AND FIGURES 
Figure 1: CONSORT 2010 Flow Diagram. Flow diagram of the progress through the phases of the 
randomized trial from enrolment, intervention allocation, follow-up to completion.  
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Abbreviation: NAC: N-acetylcysteine. 
 
 
 
 
 
Table 1: Descriptive characteristics of study participants at baseline 
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Abbreviations and notes: a: t-test, b: Parsons’s X2, c: one unit of alcohol in Demark is defined as 15 
millilitres (12 grams) of pure alcohol; BMI: Body Mass Index. Data are expressed as mean 
(Standard Deviation) or as number and percentage, depending on the type of data. No significant 
difference between treatment groups was found based on linear regression analyses. NAC: N-
acetylcysteine. 
 
 
 
 
Table 2: Pharmacological treatment at baseline 
 
Measurements 
Overall 
(n=80) 
NAC (n=40) Placebo (n=40) 
Mean Age (SD) (years) 43.4 (10.1) a 43.7 (10.0) 43.0 (10.2) 
Gender (no. of females, %) 47 (59.0%) b 26 (65.0%) 21 (52.5%) 
Number of outpatients (%) 60 (75.0%) b 31 (77.5%) 29 (72.5%) 
Diagnosis: Bipolar type I (n, (%)) 21 (26.0%) b 9 (22.5%) 12 (30.0%) 
Diagnosis: Bipolar type II (n, (%)) 59 (74.0%) b 31 (77.5%) 28 (70.0%) 
Mean age at diagnosis (SD) (years) 37.9 (9.8) a 38.4 (9.3) 37.4 (10.4) 
Mean age at onset of illness (SD) (years) 19.9 (9.8) a 20.0 (10.5) 19.9 (9.3) 
No. of depressive episodes > 10 (n, (%)) 59 (83.1%) b 28 (82.4%) 31 (83.8%) 
No. of hypomanic/manic episodes > 10 (n, (%)) 46 (66.7%) b 21 (65.6%) 25 (67.6%) 
No. of psychiatric hospitalizations (mean (SD)) 4.2 (7.8) a 3.0 (4.8) 5.4 (9.9) 
No. of patients with previous suicidal attempts (n, (%)) 32 (40.0%) b 13 (32.5%) 19 (47.5%) 
Previously ECT-treatment (n, (%)) 17 (21.3%) b 7 (17.5%) 10 (25.0%) 
Mean ECT-treatments (SD) 18.7 (12.2) a 17.6 (7.6) 19.5 (15.0) 
        
No. of cigarette smokers (n, (%)) 47 (59.0%) b 23 (57.5%) 24 (60.0%) 
Mean cigarettes pr. day (SD) 19.6 (8.4) a 20.8 (9.9) 18.4 (6.7) 
No. who drinks alcohol (n, (%)) 42 (52.5%) b 22 (55.0%) 20 (50.0%) 
Mean alcohol unitsc weekly (SD) 14.1 (25.2) a 11.5 (16.4) 16.9 (32.5) 
Drug intake prior to inclusion (n, (%)) 8 (10.0%) b 4 (10.3%) 4 (10.3%) 
Mean BMI (SD) 28.3 (6.0) a 28.3 (6.9) 28.2 (5.1) 
        
Mental Health Service Esbjerg (n, (%)) 34 (42.5%) b 17 (50.0%) 17 (50.0%) 
Mental Health Service Vejle (n, (%)) 30 (37.5%) b 14 (46.7%) 16 (53.3%) 
Mental Health Service Aalborg (n, (%)) 16 (20.0%) b 9 (56.3%) 7 (43.7%) 
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Abbreviations and notes: Data are expressed as number and percentage using a two-way table. 
Based on Parsons’s chi-squared tests no significant difference between treatment groups was 
found. NAC: N-acetylcysteine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Baseline (n (%)) 
Psychopharmacological classification Overall NAC Placebo 
Antidepressants 42 (52.5%) 21 (52.5%) 21 (52.5%) 
Antipsychotics 59 (73.8%) 29 (72.5%) 30 (75.0%) 
        Quetiapine 49 (61.3%) 25 (62.5%) 24 (60.0%) 
        Others  17 (21.3%) 08 (20.0%) 09 (22.5%) 
Mood stabilizers 42 (52.5%) 21 (52.5%) 21 (52.5%) 
        Valproate  13 (16.3%) 05 (12.5%) 08 (20.0%) 
        Lamotrigine 35 (43.8%) 20 (50.0%) 15 (37.5%) 
        Others 08 (10.0%) 06 (15.0%) 02 (05.0%) 
Lithium 27 (33.8%) 11 (27.5%) 16 (40.0%) 
Benzodiazepines 10 (12.5%) 06 (15.0%) 04 (10.0%) 
Hypnotics 13 (16.3%) 08 (20.0%) 05 (12.5%) 
No psychopharmacy 02 (02.5%) 02 (05.0%) 00 (00.0%) 
Psychotherapy 63 (78.8%) 32 (80.0%) 31 (77.5%) 
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Table 3: Primary (change in MADRS score from baseline to 20 weeks) and secondary outcome 
measures comparing NAC group and placebo group 
  NAC Placebo Baseline adjusted models 
 Mean (SD) p-value Intervention 
impact a 
95% CI 
MADRS 
 
Baseline 30.1 (7.9) 28.8 (7.1)    
2 weeks  23.0 (1.5) 23.9 (1.7) 0.34 -2.0 -6.2, 2.1 
10 weeks  18.1 (1.9) 17.7 (2.0) 0.54 -1.7 -7.2, 3.7 
20 weeks  16.3 (2.3) 15.6 (2.4) 0.88 -0.5 -7.0, 5.9 
24 weeks  13.5 (2.1) 16.8 (2.1) 0.15 -4.9 -11.6, 1.8 
Overall   0.53   
MES Baseline 21.5 (5.5) 21.1 (4.6)    
2 weeks  15.8 (1.1) 16.4 (1.2) 0.20 -1.9 -4.7, 1.0 
10 weeks  12.4 (1.3) 12.2 (1.4) 0.46 -1.4 -5.1, 2.3 
20 weeks  11.7 (1.6) 19.3 (1.5) 0.93 0.2 -4.4, 4.0 
24 weeks  9.2 (1.5) 11.6 (1.4) 0.07 -4.0 -8.3, 0.3 
Overall   0.17   
YMRS Baseline 2.3 (2.8) 1.9 (2.6)    
2 weeks  1.6 (0.3) 2.5 (0.6) 0.12 -1.3 -3.0, 0.3 
10 weeks  2.1 (0.8) 2.9 (0.7) 0.26 -1.1 -3.0, 0.8 
20 weeks  1.2 (0.6) 2.5 (0.7) 0.03* -1.6 -3.1, -0.2 
24 weeks  1.3 (0.5) 1.2 (0.5) 0.48 -0.5 -1.9, 1.0 
Overall   0.05*   
WHO Baseline 21.7 (12.6) 20.9 (16.1)    
2 weeks  35.4 (3.7) 32.0 (3.5) 0.59 2.7 -7.1, 12.4 
10 weeks  40.1 (4.6) 45.0 (4.0) 0.43 -5.0 -17.4, 7.4 
20 weeks  48.3 (4.8) 42.7 (5.7) 0.69 2.9 -11.1, 16.8 
24 weeks  51.1 (5.2) 42.3 (4.1) 0.30 7.2 -6.5, 20.9 
Overall   0.41   
GAF-F 
 
Baseline 48.7 (9.3) 49.7 (8.9)    
2 weeks  50.9 (1.5) 51.3 (1.6) 0.50 0.7 -1.4, 2.9 
10 weeks  54.7 (2.0) 54.2 (2.0) 0.42 2.0 -3.0, 6.9 
20 weeks  55.5 (2.5) 55.1 (2.5) 0.57 1.9 -4.6, 8.3 
24 weeks  59.4 (2.5) 60.3 (2.8) 0.75 1.2 -6.2, 8.6 
Overall   0.94   
GAF-S 
 
Baseline 50.6 (6.5) 51.0 (6.7)    
2 weeks  53.8 (1.2) 52.9 (1.3) 0.32 1.4 -1.4, 4.2 
10 weeks  56.7 (1.8) 55.7 (1.8) 0.44 1.7 -2.7, 6.1 
20 weeks  59.2 (2.1) 59.4 (2.0) 0.80 0.7 -4.6, 5.9 
24 weeks  61.9 (2.1) 61.8 (2.0) 0.61 1.5 -4.4, 7.4 
Overall   0.84   
CGI Baseline 4.3 (0.6) 4.3 (0.5)    
2 weeks  4.1 (0.1) 4.2 (0.1) 0.67 -0.1 -0.3, 0.2 
10 weeks  3.9 (0.1) 3.8 (0.1) 0.81 0.0 -0.3, 0.4 
20 weeks  3.5 (0.2) 3.6 (0.1) 0.70 -0.1 -0.5, 0.4 
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Abbreviations and notes: MADRS: Montgomery-Asberg Depression Rating Scale score; MES: Bech-
Rafaelsen Melancholia Scale; NAC: N-acetylcysteine; WHO-5: World Health Organization Well-
Being Index; GAF-S: The Global Assessment of Symptoms scale; GAF-F: The Global Assessment of 
Functioning scale; YMRS: Young Mania Rating Scale (YMRS)), CGI-S: The Clinical Global Impression-
24 weeks  3.4 (0.2) 3.4 (0.1) 0.81 -0.1 -0.5, 0.4 
Overall   0.94   
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Severity scale (CGI-I). A high score in MADRS, MES, CGI-S-S and YMRS represents a severe disease 
degree/level/rate, while a high score in WHO-5, GAF-F and GAF-S represents a low disease 
degree/level/rate. a: Baseline adjusted mean differences model between NAC and placebo group, 
and NAC group as reference category). *Significant at p = 0.05 
 
 
Figure 2: Margin plots of MADRS score at each visit divided by treatment groups 
 
 
Abbreviations and notes: MADRS: Montgomery-Asberg Depression Rating Scale score; NAC: N-
acetylcysteine. Testing overall study treatment by visits two-way interactions (intervention impact 
across all post-baseline visits) 
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Table 4: 
Table 4: Adverse Reactions and Serious Adverse Events reported during the study 
Adverse Reactions NAC Placebo 
NAC vs. Placebo  
(p-values) 
Headache 4 3 >0.99 
Diarrhoea 6 5 >0.99 
Nausea 8 0 0.005** 
Dizziness 3 4 >0.99 
Reflux 4 0 0.12 
Tremor 2 4 0.68 
Dry mouth 1 3 0.62 
Skin rash 2 1 >0.99 
Heartburn 2 0 0.50 
Increased sweat  2 2 >0.99 
Obstipation 2 2 >0.99 
Blurred vision 1 1 >0.99 
Stomach pains 1 1 >0.99 
Tinnitus 1 1 >0.99 
 
Adverse Reactions in total (n=66) 39 27 0.23 
 
Serious Adverse Events NAC Placebo 
NAC vs. Placebo 
(p-value) 
Psychiatric hospital admission 5 5 >0.99 
Medical hospital admission 4 1 0.40 
Acute increase suicidal 1 2 >0.99 
 
Serious Adverse Events in total (n=18) 10 8 0.20 
 
Abbreviations: The p-values are based on Fisher’s exact probability test. *Significant at p = 0.005. 
NAC: N-acetylcysteine. 
 
 
 
 
 
